506 related articles for article (PubMed ID: 22665815)
41. Changes in use of lipid-lowering medications among black and white dual enrollees with diabetes transitioning from Medicaid to Medicare Part D drug coverage.
Adams AS; Madden JM; Zhang F; Soumerai SB; Gilden D; Griggs J; Trinacty CM; Bishop C; Ross-Degnan D
Med Care; 2014 Aug; 52(8):695-703. PubMed ID: 24988304
[TBL] [Abstract][Full Text] [Related]
42. [Adherence to antihypertensive and lipid-lowering medications: a problem of public health, not yet resolved].
Grosso G; Raciti T; Marventano S; Romeo I; Mistretta A
Ann Ig; 2011; 23(2):173-84. PubMed ID: 21770233
[TBL] [Abstract][Full Text] [Related]
43. Generic-only drug coverage in the Medicare Part D gap and effect on medication cost-cutting behaviors for patients with diabetes mellitus: the translating research into action for diabetes study.
Duru OK; Mangione CM; Hsu J; Steers WN; Quiter E; Turk N; Ettner SL; Schmittdiel JA; Tseng CW
J Am Geriatr Soc; 2010 May; 58(5):822-8. PubMed ID: 20406312
[TBL] [Abstract][Full Text] [Related]
44. Persistence with biologic therapies in the Medicare coverage gap.
Tamariz L; Uribe CL; Luo J; Hanna JW; Ball DE; Krohn K; Meadows ES
Am J Manag Care; 2011 Nov; 17(11):753-9. PubMed ID: 22084895
[TBL] [Abstract][Full Text] [Related]
45. Antiparkinson drug use and adherence in medicare part D beneficiaries with Parkinson's disease.
Wei YJ; Palumbo FB; Simoni-Wastila L; Shulman LM; Stuart B; Beardsley R; Brown C
Clin Ther; 2013 Oct; 35(10):1513-1525.e1. PubMed ID: 24139423
[TBL] [Abstract][Full Text] [Related]
46. The effect of Medicare Part D on drug and medical spending.
Zhang Y; Donohue JM; Lave JR; O'Donnell G; Newhouse JP
N Engl J Med; 2009 Jul; 361(1):52-61. PubMed ID: 19571283
[TBL] [Abstract][Full Text] [Related]
47. Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: a retrospective cohort study.
Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
Clin Ther; 2009 Oct; 31(10):2178-88; discussion 2150-1. PubMed ID: 19922889
[TBL] [Abstract][Full Text] [Related]
48. Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs.
Jung K; McBean AM; Kim JA
J Manag Care Pharm; 2012 Mar; 18(2):106-15. PubMed ID: 22380470
[TBL] [Abstract][Full Text] [Related]
49. Use of generic cardiovascular medications by elderly Medicare beneficiaries receiving generalist or cardiologist care.
Federman AD; Halm EA; Siu AL
Med Care; 2007 Feb; 45(2):109-15. PubMed ID: 17224772
[TBL] [Abstract][Full Text] [Related]
50. Association of Part D coverage gap with COPD medication adherence.
Yu YF; Hearld LR; Qu H; Ray MN; Kilgore ML
Am J Manag Care; 2016 Aug; 22(8):e275-82. PubMed ID: 27556829
[TBL] [Abstract][Full Text] [Related]
51. Factors associated with medication nonadherence among Medicare low-income subsidy beneficiaries with diabetes, hypertension, and/or heart failure.
Steve Tsang CC; Browning J; Todor L; Dougherty S; Hohmeier KC; Sam Li M; Borja-Hart N; Hines LE; Wang J
J Manag Care Spec Pharm; 2021 Aug; 27(8):971-981. PubMed ID: 34337985
[No Abstract] [Full Text] [Related]
52. Impact of Medicare Part D on antidepressant treatment, medication choice, and adherence among older adults with depression.
Donohue JM; Zhang Y; Aiju M; Perera S; Lave JR; Hanlon JT; Reynolds CF
Am J Geriatr Psychiatry; 2011 Dec; 19(12):989-97. PubMed ID: 22123272
[TBL] [Abstract][Full Text] [Related]
53. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
[TBL] [Abstract][Full Text] [Related]
54. Impact of drug plans on adherence to and the cost of antihypertensive medications among patients covered by a universal drug insurance program.
Després F; Perreault S; Lalonde L; Forget A; Kettani FZ; Blais L
Can J Cardiol; 2014 May; 30(5):560-7. PubMed ID: 24613090
[TBL] [Abstract][Full Text] [Related]
55. How Medicare Part D benefit phases affect adherence with evidence-based medications following acute myocardial infarction.
Stuart B; Davidoff A; Erten M; Gottlieb SS; Dai M; Shaffer T; Zuckerman IH; Simoni-Wastila L; Bryant-Comstock L; Shenolikar R
Health Serv Res; 2013 Dec; 48(6 Pt 1):1960-77. PubMed ID: 23742013
[TBL] [Abstract][Full Text] [Related]
56. First-year Medicare Part D prescription drug benefits: medication access and continuity among dual eligible psychiatric patients.
West JC; Wilk JE; Rae DS; Muszynski IL; Rubio-Stipec M; Alter CL; Sanders KE; Crystal S; Regier DA
J Clin Psychiatry; 2010 Apr; 71(4):400-10. PubMed ID: 19925748
[TBL] [Abstract][Full Text] [Related]
57. Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs.
Hsu J; Fung V; Price M; Huang J; Brand R; Hui R; Fireman B; Newhouse JP
JAMA; 2008 Apr; 299(16):1929-36. PubMed ID: 18430912
[TBL] [Abstract][Full Text] [Related]
58. Impact of restrictive prescription plans on heart failure medication use.
Thanassoulis G; Karp I; Humphries K; Tu JV; Eisenberg MJ; Pilote L
Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):484-90. PubMed ID: 20031881
[TBL] [Abstract][Full Text] [Related]
59. Potential impact of pharmacist interventions to reduce cost for Medicare Part D beneficiaries.
Thatcher EE; Vanwert EM; Erickson SR
J Pharm Pract; 2013 Jun; 26(3):248-52. PubMed ID: 23178417
[TBL] [Abstract][Full Text] [Related]
60. The effect of the Medicare Part D benzodiazepine exclusion on the utilization patterns of benzodiazepines and substitute medications.
Chen YC; Kreling DH
Res Social Adm Pharm; 2014; 10(2):438-47. PubMed ID: 23880428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
